BGLC vs LNC · rev $99.0K vs P/E 4.9, rev $9.85B
BioNexus Gene Lab Corp Common stock (BGLC) versus Lincoln National Corporation (LNC) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Lincoln National Corporation (LNC) is a insurance - life company listed on US.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported LNC revenue for 2026-06-30 was $9.85B. Net income was $1.16B. Revenue was up 85.6% from 2026-03-31 to 2026-06-30. LNC currently screens at market cap $5.94B and trailing P/E 4.9.
BGLC currently screens at market cap $6.1M. LNC currently screens at market cap $5.94B and trailing P/E 4.9.
Not investment advice. Open the BGLC and LNC stock pages for the full models.
Not investment advice.